-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse Tradegate System der Deutsche Börse AG (60%)EURSymbol 1CG-
CRISPR TherapeuticsBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol 1CG
-
CRISPR TherapeuticsBörse Börse BerlinEURSymbol 1CG
-
CRISPR TherapeuticsBörse Börse StuttgartEURSymbol 1CG
-
CRISPR TherapeuticsBörse Börse DüsseldorfEURSymbol 1CG
-
CRISPR TherapeuticsBörse Börse MünchenEURSymbol 1CG
-
CRISPR TherapeuticsBörse Börse FrankfurtEURSymbol 1CG
-
CRISPR TherapeuticsBörse Gettex System der Börse MünchenEURSymbol 1CG
-
CRISPR TherapeuticsBörse NasdaqISIN CH0334081137 WKN: A2AT0ZUSDSymbol CRSP
-
ISIN CH0334081137 WKN: A2AT0ZUSDSymbol CRSP
-
MXN
-
USD
-
Symbol 1CG
Währung
EUR
Börse
Tradegate System der Deutsche Börse AG (60%) Zeitzone: Europe/London
Firmenname
CRISPR Therapeutics AG
Marktkapitalisierung
8.806.828.960 (+- 8%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
9.480.657.920 oder 8.133.000.000
Mitarbeiter
434 (+- 6%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
410 oder 458 Mitarbeiter
KGV
124.34
EBITDA 2.869.000
Buchwert 22.516
Portrait der CRISPR Therapeutics Aktie
Das Unternehmen CRISPR Therapeutics AG aus USA beschäftigt 434 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Gesundheitsdienstleistungen tätig.
Das Unternehmen CRISPR Therapeutics AG ist in ungefähr 13 ETFs enthalten und somit eine nicht sonderlich bekannte oder beliebte Aktie. Der Spitzenreiter Global X Genomics & Biotechnology ETF gewichtet CRISPR Therapeutics mit 3,84% im ETF.
Entdecke die 6 ETFs in denen CRISPR Therapeutics AG am höchsten gewichtet ist Insgesamt in 13 ETFs enthalten
Dir gefallen die Informationen zu CRISPR Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu CRISPR Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu CRISPR Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu CRISPR Therapeutics?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
66 News & Informationen zur CRISPR Therapeutics Aktie
Nkarta – Engineering NK Cells
Shares of Nkarta Inc. (NKTX) have lost more than 170% of their value since reaching a 52-week-high of $79.16 in December, and now trade around $28..
Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results
There are still some key unanswered questions for the biotech's promising gene-editing therapy.
Crispr Therapeutics Stock: Get Ready To Bail Out – Part 2 (NASDAQ:CRSP)
I believe that the article will cement my principal assertion that Crispr Therapeutics' stock is a tad overvalued. Its treatment for sickle cell and beta thalassemia may be too expensive.
Worldwide genome editing market size to exhibit 22.9% CAGR through 2027
The ‘Global Genome Editing Market’ provides a broad perspective of the major development trends, challenges & restraints, and other revenue-generating…
Crispr Therapeutics (NASDAQ:CRSP): Get Ready To Bail Out
Crispr Therapeutics is lagging behind established pharmaceutical names. Other cheaper alternatives are on the way too. Here's why I am doubtful of CRSP's prospects in the oncology space.
Here's What Drove Gene Editing Stocks Higher This Week
The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.
Caribou Biosciences is going public. Here’s an intro to the company and their revolutionary gene-editing technology. : investing
Disclaimer and disclosure: I am not a financial advisor and none of the below research constitutes investment advice or a recommendation to buy or …
Gene Editing Stocks Are Worth A Look After Intellia’s Big Breakthrough
Intellia Therapeutics – a gene-editing company co-founded by CRISPR pioneer and Nobel prize winner Jennifer Doudna – indicated that NTLA-2001, its experimental treatment for transthyretin amyloidosis provided very promising results in an early state trial. Although the study was small, including…
New Biotechnology ETF Could Be a Stellar Second Half Idea
The Invesco Nasdaq Biotechnology ETF (IBBQ) is just a few weeks old, but even with that rookie status, it could be a stellar second half idea.
CRISPR Therapeutics AG (CRSP): Price Down $-2.5 (-1.65)% Over Past Day, Down $-1.78 (-1.18)% Over Past Hour
Global Gene Therapy Market To Reach $2.7 Billion By 2026
SAN FRANCISCO, June 29, 2021 /PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today
Hedge Funds Have Never Been This Bullish On Pegasystems Inc. (PEGA)
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors…
Is NRG Energy Inc (NRG) Going to Burn These Hedge Funds?
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers…
Meme Stocks Get Off to a Strong Start As Nasdaq Hits New Highs – 24
The WallStreetBets community has been a resounding force in the market since January causing many investors to reevaluate their positions. Here's a look going into this trading session.
Intellia Soars On Positive Results In Gene-Editing Treatment By Investing.com
Intellia Soars On Positive Results In Gene-Editing Treatment
24 Stocks Moving in Monday's Pre-Market Session
Gainers Intellia Therapeutics, Inc. (NASDAQ:NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceutica…
Potential Game-changing Bio-Technology
There are some exciting developments in the biotech arena that could potentially be game-changers in their respective fields.
Cormorant Asset Management, LLC Buys Design Therapeutics Inc, Edgewise Therapeutics Inc, Tarsus Pharmaceuticals Inc, Sells Beam Therapeutics Inc, Immunovant Inc,
GuruFocus Article or News written by insider and the topic is about:
New All-Time Highs in Nasdaq and S&P 500: What This Means For Meme Stocks – 24/7 Wall St.
The WallStreetBets community has been a resounding force in the market since January causing many investors to reevaluate their positions. Here's a look going into this trading session.
Hedge Funds Have Never Been This Bullish On Under Armour Inc (UA)
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession…
Monday’s Crypto Breakdown and Meme Stock Meltdown – 24
The WallStreetBets community has been a resounding force in the market since January causing many investors to reevaluate their positions. Here's a look going into this trading session.
CureVac (CVAC) Q4 2020 Earnings Call Transcript
CVAC earnings call for the period ending March 31, 2021.
Apis Capital Global Discovery Fund 1Q21 Commentary
Apis Capital Global Discovery Fund commentary for the first quarter ended March 31, 2021. The Fund was up 18.1% net in Q1 2021.
CRISPR Therapeutics AG (CRSP) Presents at 20th Annual Needham Virtual Healthcare Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP) 20th Annual Needham Virtual Healthcare Conference Call April 12, 2021 9:30 A.M.
CRISPR Therapeutics AG (CRSP) Management Presents at 20th Annual Needham Virtual Healthcare Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP) 20th Annual Needham Virtual Healthcare Conference Call April 12, 2021 9:30 A.M.
3 Critical Things Investors Should Look for Before Buying Clinical-Stage Biotech Stocks
They're all about lowering your risk.
Opinion: Biotech stocks are a buy — especially these 18 picks
The sector's recent pullback offers an chance to get into exciting areas of biotech research like gene editing and oncology at better prices.
7 ARKK Stocks With Technical Support And Upside Potential
The ARK Innovation ETF (NYSE: ARKK) had another rough morning on Friday as its brutal month continues. Shares of the popular tech ETF are now down 18.9% in …
My Top Health Stock for 2021
This company has what it takes to generate earnings growth in the near term and the long term.
7 Stocks Riding 3 Unstoppable Trends That Will Make You Richer in 2021 (and Beyond)
A growing list of megatrends offers investors the opportunity to generate significant returns.
EDGAR Filing Documents for 0001193125-21-010082
Stocks That Hit 52-Week Highs On Friday
This morning 150 companies reached new 52-week highs.
Interesting Points: Eli Lilly (NYSE:LLY) was the largest firm by market cap to set a new …
The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 14) 10X …
CRISPR, Editas, Intellia: Gene Editing Stocks To Play The Next Revolution In Medicine
Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism’s genome, helping to replace the defective genes responsible for a medical condition with healthy versions. This technology is being used to develop treatments for a…
3 Groundbreaking Genomics Stocks To Buy No
Stocks Analysis by MarketBeat.com (Sean Sechler) covering: Pacific Biosciences of California, InVitae Corp, Crispr Therapeutics AG. Read MarketBeat.com (Sean Sechler)'s latest article on Investing.com
Portfolio Manager Thinks Gene-Editing Stocks Could Outperform Tesla
Portfolio Manager Thinks Gene-Editing Stocks Could Outperform Tesla, Stocks: TSLA,EDIT,CRSP,NTLA,ARKG,PACB,FATE,NVTA,IOVA,EXAS, release date:Jan 08, 2021
Stocks That Hit 52-Week Highs On Friday
This morning 470 companies set new 52-week highs.
Facts of Interest: Tesla (NASDAQ:TSLA) was the largest firm on a market cap basis to set a …
The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 7) …
Here’s the Popular Robinhood Stock Most Likely to Soar in 2021
It trounced the overall market in 2020 and could do so again this year.
CRISPR Therapeutics : Corporate Presentation
?
Creating transformative gene-based medicines for serious diseases
Corporate Overview | January… | January 4, 2021